Stroke
Conditions
Keywords
Fibrinolysis, tPA
Brief summary
Revascularisation using recombinant tPA is the reference treatment of stroke. However, the efficacy of fibrinolysis is about 50%. Several factors, including the size of thrombus, have been associated with revascularisation efficacy. The aim of this prospective study is to evaluate ex vivo the effect of tPA in patients with stroke with thromboelastography and to correlate results with the clinical outcome of patients. Results may predict revascularisation in patients with stroke.
Interventions
BIOLOGICALThromboelastography
Sponsors
University Hospital, Caen
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient (\> 18 years) with a neurological deficit compatible with a neurovascular pathology eligible for fibrinolysis rtPA and having a proximal occlusion of the middle cerebral artery (segment M1 / M2) or basilar trunk objectified brain imaging (MRI angiography or angio CT).
Exclusion criteria
* Any patient with major comorbidity, a pathology of hemostasis or anticoagulant treatment (vitamin K antagonist (VKA), direct oral anticoagulant).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of revascularisation 24 hours after tPA injection using CT scan or MRI | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| Clinical evaluation using NIHSS scale | 24 hours |
Countries
France
Contacts
Primary ContactYohann REPESSE, MD PhD
Outcome results
None listed